

Meningococcal Working Group

Carol J. Baker, MD

Advisory Committee on Immunization Practices

October 24, 2007

Working Group Members

- Allen Craig
- Ciro Sumaya
- Richard Clover- AAFP
- Geoff Evans- HRSA
- Penny Dennehy- AAP
- Lucia Lee- FDA
- David Salisbury- UK
- William Shaffner- NFID
- Jon Tempte- AAFP
- Jim Turner- ACHA
- Amy Middleman- SAM
- Martin Luta
- Paul McKinney
- Paul Offit
- Georges Peter
- David Stephens
- Amanda Cohn
- Thomas Clark
- Nancy Messonnier
- Gregory Wallace
- Elaine Miller
- Eric Wientraub

2005 ACIP Recommendation

- MCV4 initially licensed for 11 - 55 year-olds
- Routine recommendation for adolescents, others at increased risk of disease
 - Two cohorts recommended for first two years of implementation (11-12 years; high school entry or 15 years)
 - Changed to all adolescents 11-18 years in June, 2007
- Children 2-10 years-old who are at increased risk of disease should continue to receive MPSV4

Activities of Working Group

Since May 2005 *MMWR* recommendation

- 3 *MMWR*'s on GBS and MCV4
- 1 *MMWR* on inadvertant administration
- 2 Notice to Readers on supply of MCV4
- 1 Notice to Readers on revised recommendation
- MCV4 licensure in 2-10 year olds approved by the FDA on October 18, 2007

Objectives of Meningococcal Session

- Summarize available data on the association between Guillian-Barré syndrome and MCV4
- Present and vote on proposed MCV4 recommendation for 2 - 10 year-olds at increased risk of meningococcal disease
- Discuss potential for routine use of MCV4 in 2 -10 year-olds in the future

Future Activities

- February 2008: Vote on recommendations for use of MCV4 in 2 - 10 year-olds
- Revise full ACIP statement